Global Human Native Antigens and Recombinant Antigens Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Human Native Antigens and Recombinant Antigens Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

An antigen is defined as being any substance capable of inducing an immune response which results in the production of antibodies. Naturally-occurring antigens include proteins derived from microbial organisms; bacterial toxins; and non-microbial substances such as pollen, egg white or incompatible blood cells. Many antigens may be produced artificially.

Widely employed within immunization programs to generate antibodies for commercialization, both native and recombinant antigens are used as essential controls within diagnostic and prognostic testing. Both forms also have considerable utility as standards in a wide range of applications.

Market Overview:

The latest research study on the global Human Native Antigens and Recombinant Antigens market finds that the global Human Native Antigens and Recombinant Antigens market reached a value of USD 167.96 million in 2022. It’s expected that the market will achieve USD 251.92 million by 2028, exhibiting a CAGR of 6.99% during the forecast period.

Strength

Development of economy and technology
Excellent performance leads to large demand

Weakness

Unbalance development by region
Technical and financial barriers

Opportunity

Technological advances and new product launches
Increasing downstream demand

Threat

Fluctuation price of raw materials and Rising labor cost
Fierce competition from huge companies and well-developed regions

Region Overview:

From 2022-2027, Europe is estimated to witness robust growth prospects.

Company Overview:

Meridian Life Science is one of the major players operating in the Human Native Antigens and Recombinant Antigens market, holding a share of 21.61% in 2020.

Meridian Life Science, Inc. is a leading large scale manufacturer of antibodies, viral antigens, recombinant proteins, PCR Enzymes, nucleotides and critical assay reagents. The company's focus is to offer products and services that help to advance the development of diagnostic assays.

BBI Solutions is a leading expert in immunoassay development and manufacturing services, and provides an extensive portfolio of products and technologies to the global research and diagnostic markets.

Segmentation Overview:

Among different product types, Recombinant Antigens segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Clinical Biochemistry segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Human Native Antigens and Recombinant Antigens market covered in Chapter 3:

Native Antigen Company
Yashraj Biotechnology Limited
Fapon Biotech Inc.
BBI Solutions
ImmunoDX
Meridian Life Science
AROTEC Diagnostics

In Chapter 4 and Chapter 14.2, on the basis of types, the Human Native Antigens and Recombinant Antigens market from 2018 to 2029 is primarily split into:

Human Native Antigens
Recombinant Antigens

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Human Native Antigens and Recombinant Antigens market from 2018 to 2029 covers:

Scientific Research
Immunodiagnostic Test
Clinical Biochemistry
ELISA Test
Lateral Tomography Test

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)